Other
Adult-Onset Still's Disease
4
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Adult-Onset Still's Disease is an early-stage landscape with 4 programs across 3 companies. The most active players are Roche, Novartis, Prism Pharmaceuticals. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 21
Approved
No programs
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody250%
Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
5
clinical trials
Completed2 · 40%
Terminated1 · 20%
Not yet recruiting1 · 20%
Active, not recruiting1 · 20%
Clinical Trials
Trial Activity
Canakinumab for Treatment of Adult-onset Still's Disease
Terminated·—·Phase 2·NCT02204293·36 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)